A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo by Bardai, Farah H. et al.
Neurobiology of Disease
A Conserved Cytoskeletal Signaling Cascade Mediates
Neurotoxicity of FTDP-17 Tau Mutations In Vivo
X Farah H. Bardai,1 Liqun Wang,1 Yamini Mutreja,2 Mythili Yenjerla,2 T. Chris Gamblin,2* and Mel B. Feany1*
1Department of Pathology, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts 02115, and 2Department of Molecular
Biosciences, University of Kansas, Lawrence, Kansas 66045
The microtubule binding protein tau is strongly implicated in multiple neurodegenerative disorders, including frontotemporal dementia
and parkinsonism linked to chromosome 17 (FTDP-17), which is caused by mutations in tau. In vitro, FTDP-17 mutant versions of tau can
reduce microtubule binding and increase the aggregation of tau, but the mechanism by which these mutations promote disease in vivo is
not clear. Here we take a combined biochemical and in vivo modeling approach to define functional properties of tau driving neurotox-
icity in vivo. We express wild-type human tau and five FTDP-17 mutant forms of tau in Drosophila using a site-directed insertion strategy
to ensure equivalent levels of expression. We then analyze multiple markers of neurodegeneration and neurotoxicity in transgenic
animals, including analysis of both males and females. We find that FTDP-17 mutations act to enhance phosphorylation of tau and thus
promote neurotoxicity in an in vivo setting. Further, we demonstrate that phosphorylation-dependent excess stabilization of the actin
cytoskeleton is a key phosphorylation-dependent mediator of the toxicity of wild-type tau and of all the FTDP-17 mutants tested. Finally,
we show that important downstream pathways, including autophagy and the unfolded protein response, are coregulated with neurotox-
icity and actin cytoskeletal stabilization in brains of flies expressing wild-type human and various FTDP-17 tau mutants, supporting a
conserved mechanism of neurotoxicity of wild-type tau and FTDP-17 mutant tau in disease pathogenesis.
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Introduction
The neuronal protein tau is a key player in multiple human neu-
rodegenerative disorders. Alzheimer’s disease, the most common
neurodegenerative disorder, is defined neuropathologically by
the combined presence of extracellular A peptides aggregated
into plaques and intracellular neurofibrillary tangles comprised
of phosphorylated and misfolded tau. While Alzheimer’s disease
does not show clear genetic linkage to the TAU locus, the familial
neurodegenerative tauopathy, frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17), is caused by
dominant missense or splicing mutations in the TAU gene (Hut-
ton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). Thus,
primary abnormalities in tau can cause progressive neurodegen-
eration. To date, 53 pathogenic tau mutations have been reported
(Cruts et al., 2012; Ghetti et al., 2015). These mutations alter
either the splicing of TAU mRNA or create missense mutations or
small deletions in the tau protein, and should provide substantial
insight into the mechanisms by which alterations in tau cause
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Significance Statement
The microtubule protein tau aggregates and forms insoluble inclusion bodies known as neurofibrillary tangles in the brain tissue
of patients with a variety of neurodegenerative disorders, including Alzheimer’s disease. The tau protein is thus widely felt to play
a key role in promoting neurodegeneration. However, precisely how tau becomes toxic is unclear. Here we capitalize on an
“experiment of nature” in which rare missense mutations in tau cause familial neurodegeneration and neurofibrillary tangle
formation. By comparing the biochemical activities of different tau mutations with their in vivo toxicity in a well controlled
Drosophila model system, we find that all mutations tested increase phosphorylation of tau and trigger a cascade of neurotoxicity
critically impinging on the integrity of the actin cytoskeleton.
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disease. Indeed, the majority of disease-causing tau mutations
cluster near the C-terminal microtubule binding domains of the
protein, and a number of FTDP-17 mutations impair the ability
of tau to bind microtubules in vitro (Hasegawa et al., 1998; Hong
et al., 1998). These finding are consistent with longstanding mod-
els of tauopathy pathogenesis in which the inability of tau to bind
microtubules promotes neurotoxicity through lack of appropri-
ate microtubule stabilization and increased availability of cytoso-
lic tau to form neurotoxic aggregates (Ghetti et al., 2015; Bodea et
al., 2016).
However, not all disease-linked mutations appear to influence
microtubule binding (DeTure et al., 2000; Combs and Gamblin,
2012). Given the neuropathological prominence of fibrillary
inclusion bodies in tauopathies, significant effort has been ex-
pended by our and other laboratories to determine whether, al-
ternatively, abnormal aggregation of mutant tau may underlie
neurotoxicity of the proteins. Indeed, a number of FTDP-17 mu-
tations do promote in vitro fibrillation of tau (Hong et al., 1998;
Gamblin et al., 2000). However, recent experiments have raised
the possibility that large fibrillar aggregates may not necessarily
underlie tau neurotoxicity in vivo. Santacruz et al. (2005) used a
repressible mouse model of tauopathy to dissociate memory def-
icits with neurofibrillary tangle density. Similarly, human tau can
be neurotoxic in Drosophila without the formation of significant
numbers of large fibrillary inclusions (Wittmann et al., 2001),
and when present the number of large inclusions can be dissoci-
ated from ongoing neurodegeneration (Colodner and Feany,
2010). These data are consistent with a larger body of evidence
supporting the pathogenicity of smaller, or oligomeric, aggre-
gates of A, -synuclein, and other toxic aggregating proteins
(Luheshi et al., 2007; Karpinar et al., 2009). Thus, the propensity
of tau to form a particular oligomeric species might correlate
better with toxicity than fibril formation. To address these issues,
we have here expressed a selected series of biochemically charac-
terized FTDP-17 mutant tau variants in Drosophila to correlate
toxicity in a well controlled in vivo setting with biochemical
features of the protein. Our results suggest that toxicity in vivo
correlates best with a cascade of actin cytoskeletal pathology trig-
gered by excessive phosphorylation of tau.
Materials and Methods
Fly stocks, genetics. The elav-GAL4, elav-GeneSwitch, and repo-GAL4 driv-
ers were obtained from Bloomington Drosophila Stock Center at Indiana
University, as was puc-lacZ (pucE69). The following fly stocks were pro-
vided by the indicated investigators: UAS-CD8-PARP-Venus, Darren
Williams (Kings College, London, United Kingdom) (Williams et al.,
2006); UAS-Atg8a-GFP, Thomas Neufeld (University of Minnesota,
Minneapolis, Minnesota) (Juhász et al., 2008); and UAS-Xbp1-EGFP,
Hyung Don Ryoo (NYU School of Medicine, New York, New York)
(Ryoo et al., 2007). All fly crosses and experiments were performed at
25°C. 0N4R wild-type (WT) and mutant tau cDNAs were transferred
from the pT7C vector into the pENTR entry vector and inserted via
recombination into the pWALIUM10-roe Drosophila expression vector.
Transgenic flies were created using the attP40 landing site (BestGene). To
analyze tau turnover, transgenes were controlled with the elav-
GeneSwitch driver. Tau was induced by feeding flies 10 mg/ml mifepris-
tone (RU486, Sigma-Aldrich) in instant food (Carolina Biological) for
2 d. Flies were analyzed after the 2 d feeding period (see Fig. 2C, Day 1),
and then at 10 and 20 d after drug withdrawal. Full genotypes for all
experiments are presented in Extended Data.
Sectioning, immunostaining and fluorescence. Adult flies were fixed in
formalin at 30 d of age and embedded in paraffin. Serial frontal 4 m
sections including the entire brain were prepared. Antigen retrieval was
performed by microwaving in sodium citrate buffer. Immunostaining
was performed with the avidin– biotin–peroxidase complex method
(Vector Laboratories). Primary antibodies included the following:
anti-human poly-(ADP-ribose)-polymerase (PARP; 1:100,000; E51,
Abcam; RRID:AB_777102); anti--galactosidase (1:500; Promega;
RRID:AB_2313752); AT8 (1:10,000, Invitrogen; RRID:AB_223647); and
anti-GFP (1:20 to 1: 5000; N86/8, UC Davis/NIH NeuroMab Facility,
Davis, CA; RRID:AB_2313651). For quantification of cleaved caspase
(UAS-CD8-PARP-Venus), JNK activation ( puc-lacZ), and activation of
the unfolded protein response (UAS-Xbp1-EGFP), the number of posi-
tive cells in the entire brain was counted. For quantification of Atg8a-
positive puncta, since the number of puncta was too large to count in the
entire brain, the number of puncta in one anatomically consistent section
through the calyx of the mushroom body was counted. The mushroom
body has been implicated in learning and memory in Drosophila. To
quantify the number of inclusions, AT8-immunopositive puncta in five
anatomically consistent consecutive sections of the anterior medulla
were counted. The medulla is a preferential site of inclusion formation in
glial tau transgenic flies (Colodner and Feany, 2010). At least six brains
were analyzed per genotype; statistical significance was established using
ANOVA with Tukey’s HSD.
For the assessment of phalloidin fluorescence, brains from 30-d-old
flies were dissected in PBS and fixed in 4% PFA on ice for 30 min. After a
10 min incubation in 0.3% Triton-X, the brains were stained with Acti-
stain 555 phalloidin (catalog #PHDH1, Cytoskeleton) at a concentration
of 14 nM for 30 min in the dark. Brains were then washed three times in
PBS for 60 min each time, mounted, and imaged using confocal micros-
copy. For quantification of fluorescence, the average pixel density from
two-dimensional projections of z-stacks for the entire brain was com-
puted using ImageJ. Three brains were analyzed per genotype; statistical
significance was established using ANOVA with Tukey’s HSD.
RNA extraction and real-time quantitative PCR. RNA was isolated from
the heads of 1-d-old flies using TRIzol solution as per the suggestion of
the manufacturer with an additional centrifugation (12,000  g, for 10
min) to remove debris before the addition of chloroform. RNA quantity
and quality were evaluated on a NanoDrop 1000 spectrophotometer.
One microgram of total RNA was used in the reverse-transcription reac-
tion (High Capacity cDNA Reverse Transcription Kit, Applied Biosys-
tems). Primers were designed using Primer Express version 3.0 (Applied
Biosystems) and were used at a final concentration of 150 nM. PCRs were
set up in a 16 l reaction volume using SYBR Green PCR Master Mix
(Applied Biosystems). PCR amplifications were performed with an Ap-
plied Biosystems Step One machine. The RpL32 ribosomal protein L32
transcript was used as an endogenous control. Primers were as follows:
tau forward, GAT CAC GCT GGG ACG TAC GG; tau reverse, GGT CAC
GTG ACC AGC AGC T; RpL32 forward, GAC CAT CCG CCC AGC ATA
C; and RpL32 reverse, CGG CGA CGC ACT CTG TT. Experiments were
run in triplicate, and the experiment was repeated four times. Statistical
significance was assessed using ANOVA with Tukey’s HSD. Significant
differences were not detected ( p  0.5).
Western blots. Fly heads were homogenized in 2 Laemmli buffer
(Sigma-Aldrich). Samples were boiled for 10 min, briefly centrifuged,
and subjected to SDS-PAGE in a 10% gel. Proteins were transferred to
nitrocellulose membranes (Bio-Rad), blocked in 2% milk in PBS with
0.05% Tween 20, and immunoblotted using the following phospho-
rylation-dependent and phosphorylation-independent anti-tau anti-
bodies: AT270 (1:10,000; Invitrogen; RRID:AB_223651); AT8 (1:10,000;
Invitrogen; RRID:AB_223647); Tau-1 (1:1000; catalog #IHCR1015-6,
Millipore; RRID:AB_2139842); AT180 (1:10,000; Invitrogen; RRID:
AB_223649); PHF1 (1:1000; a gift from Peter Davies, Feinstein Institute
for Medical Research, North-Shore Long Island Jewish Health System,
Manhasset, New York); and total tau (1:50,000; Dako; RRID:
AB_10013724). Blots were reprobed with an anti-GAPDH antibody
(1:100,000; Invitrogen; RRID:AB_10977387) to illustrate equivalent
protein loading. For quantitative analysis, densitometry was performed
and the relative level of tau phosphorylation was assessed at each phos-
phoepitope. The fold change (see Fig. 2B) was calculated by setting wild-
type tau to a value of 1 and calculating levels for the mutants relative to
wild type. Each phosphoepitope on each form of tau was assessed at least
three times. Statistical significance was established using one-way
ANOVA with post hoc test for multiple comparisons (Tukey’s HSD).
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F-actin ELISA. Freshly dissected brains from 30-d-old flies of the indi-
cated genotypes were homogenized in 50 l of actin stabilization buffer
from the G-actin/F-actin in vivo assay kit (catalog #BK037, Cytoskele-
ton). Ten microliters of the homogenate was used in the F-actin ELISA
assay (catalog #MBS702018, MyBioSource) and the assay was performed
according to the manufacturer protocol. The remainder of the homoge-
nate was used in Western blotting to ensure equal levels of total actin and
the input. Each experiment was performed with two technical replicates.
The experiments were repeated three times. Statistical significance was
assessed using ANOVA with supplementary Tukey’s HSD.
Protein expression and purification. All WT and FTDP-17 mutant pro-
teins were expressed containing a 6-histidine tag and purified by
immobilized metal affinity chromatography followed by size exclusion
chromatography, as described previously (Rankin et al., 2005). The
FTDP-17 mutations were created using the Quikchange Site-Directed
Mutagenesis Kit from Agilent. Protein concentrations were determined
using the Pierce BCA protein assay kit (catalog #23225, Thermo Fisher
Scientific) with bovine serum albumin (BSA) as a control following the
manufacturer protocol. The following mutations were generated in a
full-length 0N4R tau background contained in a pT7C vector: R5L,
S320F, S352L, G389R, and R406W.
Actin-bundling assay. Non-muscle actin binding protein biochem kit
(catalog #BK013) was purchased from Cytoskeleton. Tau actin-bundling
activity was determined by a low-speed sedimentation assay following
the manufacturer protocol to determine whether a protein of interest can
bundle F-actin (method 3). F-actin (17 M) was incubated in the pres-
ence or absence of tau protein (3.7 M) for 30 min at room temperature.
Samples were then centrifuged at 14,000  g for 10 min at room temper-
ature to separate actin bundles that pellet from actin filaments that re-
main in the supernatant. Equal volumes of supernatants and pellets were
analyzed by SDS-PAGE, and protein was detected by Coomassie Blue
staining. Gels were imaged using a ChemiDoc-It 2 Imager from UVP. The
density of the bands was determined using the histogram feature of
Adobe Photoshop CS6.
Arachidonic acid-induced polymerization. Recombinant wild-type and
mutant tau protein, at a final concentration of 2 M, was incubated in
buffer containing 0.1 mM EDTA; 5 mM dithiothreitol; 10 mM HEPES
buffer, pH 7.64; and 200 mM NaCl. Polymerization was induced by the
addition of arachidonic acid (catalog #181198-100MG, Millipore) from a
2 mM stock solution in ethanol to a final concentration 75 M (resulting
in a final concentration of 3.75% ethanol vehicle). Ethanol-only reac-
tions with tau (2 M) were performed as negative controls. Two hundred
microliter reactions in 1.5 ml Eppendorf tubes were allowed to proceed
overnight at 25°C.
Thioflavin S fluorescence. The total amount of aggregation was mea-
sured using the binding of thioflavin S (catalog #T1892) from Sigma-
Aldrich; 150 l of each reaction mixture was added to separate wells in a
96-well, white, flat-bottom plate. Thioflavin S was diluted in water to a
concentration of 0.224 g/ml, and 6 l was added to the well. The plate was
shaken for 30 s followed by incubation in the dark for 20 min. The
fluorescence shift was measured by using a Varian Cary Eclipse Fluorescence
Spectrophotometer (Agilent Technologies) with an excitation wavelength of
440 nm and an emission wavelength of 520 nm. The photomultiplier tube
voltage was set to 650 V. Readings from control reactions with 2 M protein
and without arachidonic acid (ethanol vehicle only) were used as a blank and
were subtracted from the reading for each reaction.
Transmission electron microscopy. The arachidonic acid-induced
polymerization reaction mixtures were diluted 1:10 in polymerization
buffer and 2% glutaraldehyde (catalog #16120, Electron Microscopy Sci-
ences). After a 5 min incubation, a Formvar-coated copper grid (Elec-
tron Microscopy Sciences) was placed on top of a 10 l drop of the
diluted sample for 1 min. The grid was then blotted on filter paper,
placed on a drop of water, blotted with filter paper, placed on a drop of
2% uranyl acetate, and blotted dry. The grid was then placed on another
drop of 2% uranyl acetate for 1 min and blotted dry for a final time. The
grids were examined using a TECNAI F20 XT electron microscope (FEI).
Images were collected with the Gatan Digital Micrograph Imaging Sys-
tem at a magnification of 3600. Five images were collected from each
grid and analyzed. The amount of aggregated tau in each of the images
was quantified by using Image-Pro Plus version 6.0 (Media Cybernetics).
Filaments were highlighted using the threshold feature, and the total
number of filaments per field was determined. The perimeter of each
filament was measured and divided by 2 to estimate the length of the
filament. Filaments with a length of 15 nm were excluded because it
was more difficult to distinguish objects smaller than this from the back-
ground. The average filament length was determined by calculating the
mean length of all filaments in a given image. The total amount of aggre-
gated material in each image was calculated by summing the lengths of all
filaments in an image. The number of filaments, average length of fila-
ments, and total length of filaments per image was averaged for five
different images and reported with the SD of the averages.
Experimental design and statistical analysis. For animal model studies,
all experiments were performed on six animals per genotype and time
point (histological analyses) or at least three independent replicates
(quantitative real time PCR, Western blotting, and actin stabilization
studies). Males and females were used. For in vitro biochemical studies,
experiments were repeated at least twice (actin bundling) or were quan-
tified as described in detail above (in vitro tau aggregation). Statistical
analysis was performed using ANOVA with supplementary Tukey’s
HSD. Full statistical analyses are presented in the Extended Data.
Results
To define the biochemical properties of FTDP-17 mutant forms
of tau that determine in vivo neurotoxicity, we selected a variety
of tau mutants for expression in a well characterized, aging-
dependent Drosophila model of tauopathy (Wittmann et al., 2001;
Khurana et al., 2006; Fulga et al., 2007). Mutants were chosen ini-
tially based on our prior data demonstrating a range of in vitro
aggregation characteristics, microtubule binding profiles (Gam-
blin et al., 2000, 2003; Combs and Gamblin, 2012), and in vivo
neurotoxicity (Wittmann et al., 2001; Fulga et al., 2007); and
include R5L, S320F, S352L, G389R, and R406W. We also at-
tempted to express P301L mutant human tau in flies but were
unable to obtain transgenic animals expressing mutant human
tau, perhaps reflecting excessive toxicity of the P301L mutant
protein in vivo. All isoforms of tau were expressed in the 0N4R
(no N-terminal inserts, four microtubule binding repeat) form of
tau because we have previously observed toxicity of wild-type,
R406W, and V337M 0N4R human tau when expressed in Dro-
sophila (Wittmann et al., 2001; Khurana et al., 2006; Fulga et al.,
2007). Since neurotoxicity of tau is dose dependent (Wittmann et
al., 2001), we used a site-directed insertion strategy (Bateman et
al., 2006; Bischof et al., 2007) to ensure that expression levels of
the various tau isoforms were equivalent. We inserted our tau
transgenes into the attP40 landing site (Markstein et al., 2008)
and used the bipartite UAS-GAL4 expression system (Brand and
Perrimon, 1993) and the pan-neuronal driver elav-GAL4 (Witt-
mann et al., 2001) to express human wild-type and FTDP-17-
linked mutant forms of tau. As predicted by our site-directed
insertion strategy, levels of tau expression were similar in heads
from animals expressing wild-type and mutant transgenes, as
determined by quantitative real-time PCR (Fig. 1).
In contrast, levels of tau protein differed among the different
forms of tau (Fig. 2A,B). Most strikingly, levels of tau phosphor-
ylated at the human disease-associated serine-proline (SP) or
threonine-proline (TP) motifs, AT270, AT8, AT180, and PHF1,
were increased in the R5L, G389R, and R406W variants. Western
blotting with the Tau1 antibody, which preferentially recognizes
tau lacking phosphorylation between amino acids 189 and 207
(Szendrei et al., 1993; Steinhilb et al., 2007a), is consistent with
enhanced phosphorylation at the AT8 site. The phosphospecific
antibody AT8 recognizes tau phosphorylated at serine 202 and
threonine 205.
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Although increases in phosphorylation were greater than
changes in total tau levels, there was a trend for total tau (phos-
phorylated and nonphosphorylated tau) levels to be higher in
flies expressing R5L, G389R, or R406W mutant tau compared
with wild-type tau (Fig. 2A,B and Fig. 2-1 available at https://doi.
org/10.1523/JNEUROSCI.1550-17.2017.f2-1).Todeterminewhe-
ther the stability of tau was altered by the mutants studied, the
GeneSwitch (Osterwalder et al., 2001) conditional expression
system and the elav-GeneSwitch pan-neuronal driver were used
to temporally regulate the expression of wild-type and mutant
tau variants. At day 1 following eclosion, flies were placed on
medium containing mifepristone (RU486), which induces tran-
scriptional activation in the GeneSwitch system. Flies were main-
tained on drug-embedded food for 2 d, at which time heads were
taken for Western blot analysis (Fig. 2C, Day 1). Flies were then
aged for 10 or 20 d and heads were analyzed by Western blot (Fig.
2C, Day 10 and Day 20). Flies grown on food containing the
ethanol vehicle only were used as controls (Fig. 2C, No drug).
Quantitative Western blot analysis revealed a trend toward
greater stability of tau in flies expressing R5L, G389R, and R406W
variants (Fig. 2D and Fig. 2-1 available at https://doi.org/10.1523/
JNEUROSCI.1550-17.2017.f2-1). To determine whether proline-
directed phosphorylation might drive altered stability of FTDP-17
tau variants, we used a mutant form of tau in which 14 SP and TP
sites have been mutated to glutamate to mimic phosphorylation
[Fig. 2C,D, E14]. All 14 Ser-Pro and Thr-Pro kinase target sites
were mutated to glutamate (tauE14). We have previously dem-
onstrated that E14 mutant tau is substantially more toxic that
wild-type tau (Khurana et al., 2006; Dias-Santagata et al., 2007;
Fulga et al., 2007). The E14 protein was significantly more sta-
ble in vivo than wild-type, S320F, or S352L mutant tau (Fig. 2D
and Fig. 2-1 available at https://doi.org/10.1523/JNEUROSCI.
1550-17.2017.f2-1), which is consistent with a role for phosphor-
ylation in regulating the stability of tau.
To determine whether changes in tau phosphorylation corre-
lated with neurotoxicity in our transgenic animals, we next as-
sessed the toxicity of various tau isoforms. We began by using a
well characterized transgenic reporter of caspase activity, which
correlates well with cell death in our tau transgenic Drosophila
(Loewen and Feany, 2010; Frost et al., 2014). These reporter flies
carry a transgenic construct in which the extracellular and trans-
membrane domains of mouse CD8 is fused to 40 aa from human
PARP, including the caspase cleavage site of PARP (UAS-CD8-
PARP-Venus; Williams et al., 2006). Endogenous Drosophila
caspases cleave the reporter at the PARP cleavage site. Caspase
activation is then assessed experimentally using an antibody that
is specific for cleaved human PARP. The transgenic caspase
reporter provides a robust and quantitative method to monitor
endogenous caspase activity and apoptotic cell death in adult
Drosophila models of human neurodegenerative disease (Hegde
et al., 2014; Wang et al., 2015, 2016). When we examined the
brains of 30-day-old flies (flies live for 60 d under our culture
conditions) expressing wild-type or FTDP-17 mutant forms of
human tau in neurons, we observed significantly greater num-
bers of neurons with activated caspase in flies expressing R5L,
G389R, or R406W mutant tau compared with flies expressing
wild-type tau (Fig. 3A,B and Fig. 3-1 available at https://doi.org/
10.1523/JNEUROSCI.1550-17.2017.f3-1). Note that the cells
identified are neurons because the reporter construct is expressed
only in neurons under the control of the elav-GAL4 driver, which
is consistent with the morphology of the labeled cells (Fig. 3A).
Consistent with these findings, animals homozygous (females) or
hemizygous (males, the elav-GAL4 driver is on the X-chromo-
some) for the elav-GAL4 driver and homozygous for the R5L,
G389R, or R406W tau transgenes were not viable and were thus
not recovered. In contrast, adult flies homozygous (female) or
hemizygous (male) for the elav-GAL4 driver and homozygous for
the wild-type, S320F, or S352L tau transgenes were viable.
We have previously demonstrated an important role for oxi-
dative stress in Drosophila models of tauopathy (Dias-Santagata
et al., 2007). The induction of stress-activated protein kinase
cascades, such as the JNK signaling pathway, is one of the best
characterized responses to oxidative damage (Martindale and
Holbrook, 2002; Zhu et al., 2003). To determine whether JNK
pathway activation correlated with tau-induced neurotoxicity in
our transgenic animals, we used the puckered-lacZ (puc-lacZ)
reporter system, which is commonly used to monitor JNK path-
way activation in Drosophila. The puc gene encodes a phosphatase
that inactivates JNK and other MAPK family members and is a well
established transcriptional target of JNK signaling in Drosophila
(Martín-Blanco et al., 1998). Brains from transgenic flies carrying
the puc-lacZ reporter alone or with various tau transgenes ex-
pressed in neurons were immunostained at 30 d after eclosion
with an antibody against -galactosidase. Reporter activity was
minimal in control flies, while multiple cortical cells demon-
strated staining for -galactosidase in tau transgenic animals
(Fig. 4A,B), with the greatest activation occurring in flies ex-
pressing R5L, G389R, and R406W mutant forms of tau. We have
previously demonstrated that cells with JNK activation are pre-
dominantly neurons, consistent with the morphology of the cells
labeled (Dias-Santagata et al., 2007).
Having demonstrated that increased phosphorylation of tau
correlates with established markers of neurotoxicity in our trans-
genic fly models, we next assessed aggregation of tau. Large
inclusions are infrequent in our neuronal tauopathy model (Wit-
tmann et al., 2001). However, when we express human tau in
Drosophila glia using the pan-glial driver repo-GAL4, we observe
numerous inclusions comprised of filamentous tau at the elec-
tron microscopic level (Colodner and Feany, 2010), as can be
seen in human glial tauopathies (Feany and Dickson, 1995, 1996;
Kovacs et al., 2016). We therefore expressed wild-type and
disease-linked mutant versions of tau in fly glia and examined the
brains of 30-day-old flies for the presence of tau aggregates using
Figure 1. Expression of tau in transgenic animals. Quantitative real-time PCR reveals
equivalent levels of tau transcripts in flies expressing 0N4R wild-type and FTDP-17-linked
forms of tau under the control of the pan-neuronal elav-GAL4 driver. Values are normal-
ized to wild type. Experiments were run in triplicate and the experiment was repeated at
least three times. There were no significant differences in relative transcript levels ( p 
0.5, ANOVA). Flies are 1 d old. Full genotypes are provided in Figure 1-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f1-1.
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immunostaining for the anti-tau antibody AT8 (Colodner and
Feany, 2010). The number of large tau inclusions was signifi-
cantly increased in flies expressing S320F or S352L mutant tau,
compared with animals expressing wild-type, R5L, G389R, or
R406W mutant tau (Fig. 5A,B and Fig. 5-1 available at https://
doi.org/10.1523/JNEUROSCI.1550-17.2017.f5-1), while the ex-
pression (Fig. 5C) and toxicity (Fig. 5D) of tau were similar to
neuronal and glial expression.
We have previously shown that S352L mutant tau displays
enhanced polymerization in vitro (Combs and Gamblin, 2012),
potentially correlating with increased inclusion formation in vivo
(Fig. 5A,B). However, these experiments were performed in the
2N4R tau backbone. We have demonstrated that the specific
isoform of tau can play an important role in determining key
biochemical characteristics of the protein, including aggregation
potential (Carlson et al., 2007; Voss et al., 2012; Mutreja and
Gamblin, 2017). To correlate more directly with our in vivo work,
we thus expressed mutant forms of tau in the context of the 0N4R
tau isoform, purified protein from bacterial lysates, and assessed
aggregation of the wild-type and mutant tau isoforms. Using
2 M tau in the presence of 75 M arachidonic acid to promote
polymerization (Carlson et al., 2007), we observed a trend toward
increased aggregation of S320F and S352L mutant tau, as mea-
sured by thioflavin S fluorescence, compared with wild-type tau
and the other mutant forms of tau modeled (Fig. 5E and Fig. 5-1
available at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.
f5-1). To examine the aggregates formed by each of the mutants
in more detail, we performed electron microscopy. By electron
microscopy, wild-type tau formed a mixture of longer fila-
ments and smaller aggregates. Interestingly, although both
S320F and S352L mutant tau showed more aggregation than
wild-type tau, S320F formed more (Fig. 5 F, G), relatively
Figure 2. Phosphorylation and turnover of tau in transgenic animals. A, Western blots showing the phosphorylation of tau at proline-directed sites in flies expressing tau using the pan-neuronal
elav-GAL4 driver. Tau-1 recognizes nonphosphorylated tau. The blot was reprobed with a phosphorylation-independent antibody (total tau) to assess total (phosphorylated and unphosphorylated)
tau and with an antibody to GAPDH to illustrate equivalent protein loading. All blots were repeated a minimum of three times. B, Quantitative analysis of tau phosphorylation at proline-directed sites
reveals significant increases in phosphorylation of tau at AT270 and PHF1 in flies expressing R5L, G389R, or R406W mutant tau compared with flies expressing wild-type tau ( p  0.05, Tukey’s HSD).
Control is elav-GAL4/. Full genotypes are provided in Figure 2-1 available at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f2-1. Flies are 1 d old. C, Tau turnover following conditional
expression of tau variants in adult neurons using the elav-GeneSwitch driver. Full genotypes are provided in Figure 2-1 available at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f2-1. The blot
was reprobed with an antibody to GAPDH to illustrate equivalent protein loading. All blots were repeated four times. D, Quantitative analysis of tau turnover reveals that WT, S320F, and S352L are
less stable than R406W and E14 ( p  0.05, Tukey’s HSD). Full statistical analysis is presented in Figure 2-1 available at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f2-1.
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smaller filaments, while S352L promoted the formation of
longer filaments (Fig. 5 F, H,I ). The other mutants studied,
R5L, G389R, and R406W, had an aggregation profile more
similar to wild type, which is consistent with a primary effect
of the mutations on the phosphorylation, not the intrinsic
aggregation, of tau.
We have previously demonstrated that phosphorylation-
dependent stabilization of actin by tau is a critical downstream
mediator of neurotoxicity (Fulga et al., 2007; DuBoff et al., 2012;
Frost et al., 2016). We therefore assessed the degree of F-actin
polymerization in brains from flies expressing tau transgenes in
neurons using the elav-GAL4 driver. Staining for F-actin with
fluorescently labeled phalloidin revealed a trend toward in-
creased levels of F-actin in flies expressing human tau, including
wild-type tau and all the FTDP-17 linked forms of mutant tau
modeled. In addition, R5L, G389R, or R406W mutant tau had a
significant increase in phalloidin staining compared with wild-
type tau (Fig. 6A,B and Fig. 6-1 available at https://doi.org/10.
1523/JNEUROSCI.1550-17.2017.f6-1). To assess actin stabiliza-
tion using a different method, we used an F-actin ELISA, which
uses a monoclonal antibody specific for F-actin. Similar to the
results with phalloidin fluorescence, we demonstrated a trend
toward increased levels of F-actin in brains from animals express-
ing R5L, G389R, or R406W using the F-actin ELISA (Fig. 6C
and Fig. 6-1 available at https://doi.org/10.1523/JNEUROSCI.
1550-17.2017.f6-1).
Although previous data from our laboratory have suggested
that phosphorylation of tau is a key determinant of actin-stabilizing
activity in vivo (Fulga et al., 2007), FTDP-17-linked variants
might additionally or alternatively have altered intrinsic ability to
bind and stabilize F-actin. To address this possibility directly, we
incubated purified F-actin filaments with tau in vitro and used
low-speed centrifugation to pellet actin filaments (Fulga et al.,
2007). We used -actinin (-act), a major actin cross-linking pro-
tein (Foley and Young, 2014), as a positive control, and BSA as a
negative control. As expected, we observed increased amounts of
pelleted actin following incubation with -act and no significant
bundling using BSA, and confirmed our prior observation (Fulga et
al., 2007) of bundling activity of wild-type human tau in vitro (Fig.
6D–F). The amounts of actin recovered in the pellet (Fig. 6D,E) and
protein bound in the pellet (Fig. 6D,F) were similar when compar-
ing wild-type tau with the FTDP-17 mutant forms of tau studied
here, which is consistent with phosphorylation of tau as the key
determinant of actin binding and stabilization.
Proteostasis, or protein homeostasis, is a critical cellular re-
sponse to the accumulation of misfolded and aggregated proteins
and is controlled by autophagy and the unfolded protein re-
sponse (Labbadia and Morimoto, 2015). We have previously
demonstrated that both autophagy and the endoplasmic reticu-
lum unfolded protein response are activated in response to hu-
man tau expression in aging fly neurons (Loewen and Feany,
2010; Merlo et al., 2014). To determine whether expression of the
range of mutant forms of tau modeled in the current study sim-
ilarly perturbs pathways controlling proteostasis, we used trans-
genic markers of autophagy and the unfolded protein response.
The UAS-Atg8a-GFP reporter is commonly used to assess the
activation of autophagy in Drosophila (Klionsky et al., 2016).
Atg8a is the fly homolog of LC3. When we expressed UAS-
Atg8a-GFP along with wild-type or mutant tau and stained the
brains of aged flies for GFP, we observed increased numbers of
GFP-immunoreactive puncta in flies expressing tau in neu-
rons (Fig. 7 A, B and Fig. 7-1 available at https://doi.org/10.
1523/JNEUROSCI.1550-17.2017.f7-1), which is consistent with
our prior observations (Merlo et al., 2014). Of note, the three
Figure 3. Caspase cleavage in tau transgenic animals. A, Neurons with activated caspase as
monitored by cleavage of the transgenic reporter UAS-CD8-PARP (40 aa at caspase cleavage
site)-Venus in flies expressing tau using the pan-neuronal elav-GAL4 driver. Arrows indicate
cells with caspase activation. Scale bar, 3 m. B, Quantitative analysis of the number of neurons
with activated caspase in the entire brains of control animals or in flies expressing human
wild-type or FTDP-17 mutant forms of tau. Six brains were analyzed per genotype. Control is
elav-GAL4/; UAS-CD8-PARP-Venus/. Full genotypes are provided in Figure 3-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f3-1. Flies are 30 d old. **p  0.01, *p 
0.05, ANOVA with Tukey’s HSD. Full statistical analysis is presented in Figure 3-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f3-1.
Figure 4. Stress pathway activation in tau transgenic animals. A, Neurons with activated
JNK signaling as monitored by the puc-lacZ reporter and immunostaining for -galactosidase,
which is directed to the nucleus (Bier et al., 1989), in flies expressing tau using the pan-neuronal
elav-GAL4 driver. Arrows indicate positive nuclei. Scale bar, 10 m. B, Quantitative analysis of
the number of neurons with activated JNK in the entire brains of control animals, or in flies
expressing human wild-type or FTDP-17 mutant forms of tau. Six brains were analyzed per
genotype. Control is elav-GAL4/; puc-lacZ/. Full genotypes are provided in Figure 4-1 avail-
able at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f4-1. Flies are 30 d old. **p  0.01,
ANOVA with Tukey’s HSD. Full statistical analysis is presented in Figure 4-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f4-1.
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Figure 5. In vivo and in vitro aggregation of tau. A, Inclusions as identified by AT8 immunostaining in tissue sections from flies expressing tau using the pan-glial repo-GAL4 driver. Arrows indicate
inclusions. Scale bar, 10 m. B, Quantitative analysis of the number of inclusions in sections from the midportion of the medulla neuropil in control animals or in flies expressing human wild-type
or FTDP-17 mutant forms of tau. Six brains were analyzed per genotype. C, Western blot analysis showing the expression of tau expressed in glia. The blot is reprobed for GAPDH to illustrate
equivalent protein loading. Control is repo-GAL4/ in A–C. D, Quantitative analysis of the number of neurons with activated caspase in the entire brains (Figure legend continues.)
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most toxic versions of tau, R5L, G389R, and R406W, resulted in
the greatest activation of autophagy, as monitored by our trans-
genic reporter.
To assess the activity of the unfolded protein response in our
transgenic flies, we used a UAS-Xbp1-EGFP reporter system de-
veloped by Ryoo et al. (2007). Xbp1 is a central transcription
factor controlling the expression of a variety of genes integral to
the expression of the unfolded protein response. In the reporter
construct, EGFP is located after the IRE-1 splice site in Xbp1 such
that EGFP is only in frame after Xbp1 has been spliced by IRE-1.
Thus, the UAS-Xbp1-EGFP transgene acts as a reporter for the
4
(Figure legend continued.) of control animals or in flies expressing human wild-type or FTDP-17
mutant forms of tau. Six brains were analyzed per genotype. Control is UAS-CD8-PARP-Venus/
repo-GAL4. Full genotypes are provided in Figure 5-1 available at https://doi.org/10.1523/
JNEUROSCI.1550-17.2017.f5-1. Flies are 30 d old in A–D. E, Polymerization of tau measured by
thioflavin S staining. F, Electron micrographs of polymerization reaction mixtures. G–I, Quan-
tification of polymerized tau protein in electron micrographs. The graphs display the total
number of tau filaments per image (G), the mean length of filaments (in nanometers; H), and
the total length of filaments (I). Images in the electron micrographs (F) were quantified using
Image-Pro Plus version 6.0, as described in the Materials and Methods. ***p  0.001, ANOVA
with Tukey’s HSD. Full statistical analysis is presented in Figure 5-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f5-1.
Figure 6. Interaction of tau with actin in vivo and in vitro. A, F-actin staining with fluorescent phalloidin in whole fly brains from flies expressing tau using the pan-neuronal elav-GAL4 driver. Scale
bar, 50 m. B, Quantitative analysis of phalloidin fluorescence in the brains of control animals or flies expressing human wild-type or FTDP-17 mutant forms of tau. Three brains were analyzed per
genotype. C, F-actin ELISA in homogenates of brains from control animals or flies expressing human wild-type or FTDP-17 mutant forms of tau. Each experiment was performed with two technical
replicates. The experiments were repeated three times. *p  0.05, ANOVA with Tukey’s HSD. Full statistical analysis is presented in Figure 6-1 available at https://doi.org/10.1523/JNEUROSCI.
1550-17.2017.f6-1. Control is elav-GAL4/. Full genotypes are provided in Figure 6-1 available at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f6-1. Flies are 30 d old. D–F, Increased
amounts of F-actin are recovered in the pellet following incubation with -act as a positive control or with human wild-type or FTDP-17 mutant forms of tau (D), as assessed by quantitative analysis
of the amount of pelleted actin (E) or protein bound in the pellet (F). BSA is used as a negative control. The experiment was repeated twice.
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activation of the unfolded protein response because the expres-
sion of EGFP indicates that Xbp1 has been cleaved by IRE-1.
When we expressed UAS-Xbp1-EFGP with human tau, we found
induction of the reporter (Fig. 8A,B and Fig. 8-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f8-1) with
expression of wild-type or mutant human tau in neurons, which
is consistent with our prior results (Loewen and Feany, 2010).
Further, we observed that variants of tau with enhanced neuro-
toxicity, R5L, G389R, and R406W, were most effective in pro-
moting the activation of the unfolded protein response. Note that
for the analysis of autophagy and the unfolded protein response,
we monitored pathway activity in neurons because the neuronal-
specific driver elav-GAL4 was used to express the reporter trans-
genes. Neuronal activation of the reporters is consistent with cell
morphology (Figs. 7A, 8A) and with prior double-labeled immu-
nofluorescence analyses (Loewen and Feany, 2010; Merlo et al.,
2014).
Discussion
The 53 known mutations in tau that cause neurodegeneration
and neurofibrillary tangle formation in the context of the inher-
ited and severe form of frontotemporal dementia, FTDP-17,
should provide important mechanistic clues into the biophysical
and cell biological determinants of tau neurotoxicity. Such in-
sights would be of direct relevance to the pathogenesis of FTDP-17
and might also inform our understanding of more common
tauopathies, including Alzheimer’s disease, which are character-
ized by the deposition of wild-type tau into insoluble aggregates.
However, while studies to date have tended to provide broad
support for the loss of microtubule binding and increased aggre-
gation in mediating the toxic effects of FTDP-17-linked missense
mutations in tau (Ghetti et al., 2015), not all mutations have clear
effects on microtubule binding or aggregation of tau in vitro.
Thus, another specific feature of the protein might drive toxicity
in vivo. Alternatively, there may be multiple mechanisms by
which mutations in tau promote neurodegeneration. To address
these possibilities experimentally, we have used an in vivo model
of tau toxicity that allows the expression of multiple tau variants
at the same levels and the assessment of relevant neuropatholog-
ical and biochemical phenotypes in parallel.
We find a striking correlation of neurotoxicity with phos-
phorylation of tau in FTDP-17 mutants (Figs. 2, 3). These find-
ings fit well with prior results in Drosophila tauopathy models
demonstrating that altering expression of kinases and phospha-
tases modifies tau neurotoxicity (Jackson et al., 2002; Shulman
and Feany, 2003; Steinhilb et al., 2007b). In addition, the muta-
tion of SP and TP sites to alanine to block phosphorylation re-
duces tau neurotoxicity, while the mutation of the same SP and
TP sites to glutamate to mimic phosphorylation strongly pro-
motes tau neurotoxicity in our transgenic Drosophila (Fulga et al.,
2007; Steinhilb et al., 2007a, 2007b). Our results are also consis-
tent with the analysis of patient tissue demonstrating increased
phosphorylation of tau in postmortem brain from patients with
FTDP-17 (Reed et al., 1997, 2001; Miyasaka et al., 2001). Inter-
estingly, FTDP-17 mutant tau tends to be less phosphorylated
compared with wild-type tau in cell culture (Mack et al., 2001;
DeTure et al., 2002), which may reflect differences between in
vivo and in vitro conditions, and emphasizes the role of in vivo
modeling to complement biochemical and cell culture studies. It
is not currently clear how the mutations we studied promote the
phosphorylation of tau. Increased propensity for phosphoryla-
tion at disease-linked sites may be an intrinsic property of
FTDP-17 mutant tau. Alonso Adel et al. (2004) demonstrated a
Figure 7. Autophagy in tau transgenic animals. A, Activation of autophagy in flies express-
ing tau using the pan-neuronal elav-GAL4 driver as monitored by the accumulation of the
transgenic reporter UAS-Atg8a-GFP and immunostaining for GFP. Arrows indicate GFP-positive
puncta. Scale bar, 3 m. B, Quantitative analysis of the number of puncta in a section through
the calyx of the mushroom body in the brains of control animals, or flies expressing human
wild-type or FTDP-17 mutant forms of tau. Six brains were analyzed per genotype. Control is
elav-GAL4/; UAS-Atg8a-GFP/. Full genotypes are provided in Figure 7-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f7-1. Flies are 30 d old. ***p  0.001,
ANOVA with Tukey’s HSD. Full statistical analysis is presented in Figure 7-1 available at
https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f7-1.
Figure 8. Unfolded protein response in tau transgenic animals. A, Neurons with activation of
the unfolded protein response in flies expressing tau using the pan-neuronal elav-GAL4 driver as
monitored by the transgenic reporter UAS-Xbp1-EGFP and immunostaining for GFP. GFP is
directed to the nucleus via the Xbp1 nuclear localization sequence (Ryoo et al., 2007). Arrows
indicate GFP-positive nuclei. Scale bar, 10 m. B, Quantitative analysis of the number of neu-
rons with activation of the unfolded protein response in the entire brains of control animals or
flies expressing human wild-type or FTDP-17 mutant forms of tau. Six brains were analyzed per
genotype. Control is elav-GAL4/; UAS-Xbp1-EGFP/. Full genotypes are provided in Figure
8-1 available at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f8-1. Flies are 30 d old.
*p  0.05, ANOVA with Tukey’s HSD. Full statistical analysis is presented in Figure 8-1 available
at https://doi.org/10.1523/JNEUROSCI.1550-17.2017.f8-1.
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substantially increased rate and steady-state in vitro phosphory-
lation of FTDP-17 tau variants, including the R406W mutant
studied here. Although the G389R and R406W mutations are in
the C-terminal portion of the tau protein, near the proline-
directed phosphorylation sites we study, the R5L mutation is in
the N terminus of the protein. Thus, structural interactions be-
tween the N and C termini of tau, as are known to occur (Jega-
nathan et al., 2006), may influence kinase access and efficiency.
Alternatively, FTDP-17 mutations may alter another aspect of
structure, localization, or activity that secondarily influences
phosphorylation.
In addition to a strong effect on increasing tau phosphoryla-
tion, FTDP-17 variants showed a trend toward altering total lev-
els of tau (Fig. 2A,B and Fig. 2-1 available at https://doi.org/10.
1523/JNEUROSCI.1550-17.2017.f2-1). Since mRNA expression
of tau variants was similar (Fig. 1), as expected given the site-
directed transgenesis approach, we used the GeneSwitch-regulated
expression system to determine whether the stability of the mu-
tant tau proteins was altered in neurons. Consistent with results
from Western blot analysis (Fig. 2A), we found a trend toward
increased stability of the mutant tau variants (R5L, G389R, and
R406W) that also tended to have the higher levels of total tau
(Fig. 2 A, B and Fig. 2-1 available at https://doi.org/10.1523/
JNEUROSCI.1550-17.2017.f2-1). The significantly increased sta-
bility of the pseudohyperphosphorylated E14 tau mutant (Fig. 2A,B
and Fig. 2-1 available at https://doi.org/10.1523/JNEUROSCI.
1550-17.2017.f2-1) supports a role for proline-directed serine and
threonine phosphorylation of tau in promoting the stability of
the protein in vivo. Further, the enhanced stability of the E14
variant is consistent with a primary effect of FTDP-17 mutants on
phosphorylation with consequent altered stability. Interestingly,
our finding that tau turns over in 6 d in the fly brain is similar to
the half-life of 10 d reported in a transgenic mouse model of
tauopathy (Yamada et al., 2015) and is significantly greater than
the half-life of tau typically observed in cell culture (David et al.,
2002; Lim et al., 2008).
In contrast to flies expressing R5L, G389R, or R406W mutant
tau, animals expressing S320F or S352L mutant tau showed less
neurotoxicity and activation of downstream pathways in our in
vivo models. The S320F mutation has been linked to frontotem-
poral dementia of relatively early onset in multiple studies (Rosso
et al., 2002, 2003; Rohrer et al., 2009, 2010). Interestingly, the
S352L mutation is apparently manifest only in the homozygous
state, with heterozygous carriers being normal (Nicholl et al.,
2003), which is possibly consistent with a more modest clinical
effect of the mutation. Strikingly, both S320F and S352L mutant
tau aggregate more readily than the other FTDP-17 variants we
studied into large inclusions in transgenic flies (Fig. 5A,B). The
enhanced in vivo propensity for aggregate formation correlates
well with in vitro aggregation as measured by thioflavin S fluores-
cence (Fig. 5E). Of note, although total aggregation is enhanced in
vitro in both mutants, S320F mutant tau forms more and shorter
aggregates, while S352L mutant tau aggregates into long filaments
(Fig. 5F–I). Our transgenic data suggest that both types of aggregates
deposit effectively into large inclusions in vivo. Further, since the
propensity toward increased aggregation in vitro is associated with
relatively less neurotoxicity and the formation of large inclusion
bodies in vivo, our finding raises the possibility that the therapeutic
approaches aimed at promoting the incorporation of smaller, toxic
aggregates into larger, less toxic, or inert inclusion bodies may be
beneficial. Prior work in our laboratory (Wittmann et al., 2001;
Colodner and Feany, 2010) and by other investigators (Santacruz et
al., 2005; de Calignon et al., 2010) is consistent with the dissociation
of neurofibrillary tangles from neurotoxicity.
The degree to which different FTDP-17-linked mutations ac-
tivate the same downstream cascade of neurotoxicity, and the
relationship of the mechanism of toxicity of mutant tau to that of
the wild-type protein, have been unclear. Here we significantly
expand our prior work to provide evidence for shared mecha-
nisms of toxicity. We have previously shown that wild-type and
R406W mutant human tau activate common downstream mech-
anisms of toxicity (Khurana et al., 2006; Dias-Santagata et al.,
2007; Fulga et al., 2007; Loewen and Feany, 2010; Frost et al.,
2014, 2016). We now confirm and extend these findings by dem-
onstrating that F-actin is stabilized by wild-type tau and by all the
mutant forms of tau we study, both in vivo (Fig. 6A,B) and in
vitro (Fig. 6D–F), and that stabilization of actin correlates well
with neurotoxicity. A separate study by another group suggests
that two additional FTDP-17 variants, P301L and V337M,
likewise promote tau neurotoxicity in vivo through excess sta-
bilization of F-actin (Zhou et al., 2017). The increased in vivo
stabilization of the actin cytoskeleton observed with the expres-
sion of the most toxic forms of tau most likely reflects hyperphos-
phorylation of these mutants. We have previously demonstrated
that phosphorylation is upstream of, and strongly promotes, sta-
bilization of actin by tau (Fulga et al., 2007). In our current work,
we see no increase of in vitro bundling of tau with more toxic
versus less toxic variants of tau (Fig. 6D–F), which is consistent
with a primary effect of phosphorylation on actin stabilization.
Other downstream pathways modulating tau neurotoxicity are
similarly activated by all the forms of tau we study here, in pro-
portion with in vivo toxicity including stress pathway activation
(Fig. 4), increased autophagy (Fig. 7) and induction of the un-
folded protein response (Fig. 8). Thus, despite differences in the
relative toxicity of different isoforms, studying the pathogenesis
of a single form of mutant tau, as is often done experimentally, is
likely to be highly relevant to the larger group of tauopathies, includ-
ing Alzheimer’s disease and other tauopathies characterized by the
aggregation and deposition of wild-type tau. These results may have
important therapeutic implications because treatments that are ef-
fective for one tauopathy may work in a wide range of disorders
characterized by abnormal tau deposition.
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